Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
397.50    2.00 (0.51%)
Bid:
390.00
Ask:
405.00
Spread: 15.00 (3.846%)
Market Cap: £190.07m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

Supply and Distribution Agree

23 Jun 2008 07:00

RNS Number : 2319X
Tristel PLC
23 June 2008
ย 

๏ปฟ

ย 

TRISTEL plc

Supply and distribution agreement with Bio-Cide International, Inc.,ย United States,ย and representation in the Biocidal Products Directive

Tristel plc ("Tristel"ย or the "Group"), the AIM listed provider of infection and contamination control products, announces that it has entered into a newย 20ย year supply agreement with Bio-Cide International, Inc. ("BCI"), Oklahoma, United States.ย Additionally, Tristelย hasย nowย beenย appointedย asย the distributor for BCI's productsย throughout the European Union.ย Tristel had previously been BCI's distributorย onlyย in theย United Kingdom.

BCI is a manufacturer of a proprietary sodium chlorite solution, which is a key component in Tristel's chlorine dioxide products. BCI has been supplying its sodium chlorite chemistry to Tristel's legionella control and food contamination control subsidiary, Tristel Technologies, for over ten years.ย The enlarged relationship with BCI signals Tristel's intention to expand its legionella, food and horticulture contamination control business throughoutย Europe.

BCI is one of three industry partners that form the registration group for sodium chlorite/chlorine dioxide under the European Biocidal Products Directive ("BPD"), whichย is set toย fashion the shape of the biocides industry inย Europe. In conjunction with the new supply and distribution agreement, Tristel becomes BCI's representative within the BPD, placingย Tristel at the heart of chlorine dioxide's future within the European marketplace.

For further information contact:

Tristel plc

Paul Swinney, Chief Executive

Tel: 01638 721 500

Daniel Stewart & Company Plc

Graham Webster

Tel: 020 7776 6576

Parkgreen Communications Ltd

Tel: 020 7479 7933

Paul McManus

Mob: 07980 541 893

paul.mcmanus@parkgreenmedia.com

This information is provided by RNS
The company news service from the London Stock Exchange
ย 
END
ย 
ย 
AGRILFSERIIIFIT
Date   Source Headline
10th Apr 20257:00 amRNSAdditional info. submitted to FDA for Tristel OPH
9th Apr 20257:00 amRNSPublication of Poster by Mayo Clinic & US update
2nd Apr 20257:00 amRNSDirector/PDMR Shareholding
31st Mar 20258:56 amRNSHolding(s) in Company
26th Mar 202510:30 amRNSDirector/PDMR Shareholding
18th Mar 20252:39 pmRNSHolding(s) in Company
24th Feb 20257:00 amRNSUnaudited Interim Results
7th Feb 20257:00 amRNSExercise of Share Options and Total Voting Rights
23rd Jan 20257:00 amRNSDirector Option Grant
13th Jan 20257:00 amRNSConfirmation of Interim Results
16th Dec 20242:45 pmRNSResult of AGM
16th Dec 20247:00 amRNSAGM Statement and Notice of Interim Results
22nd Nov 202410:30 amRNSNotice of AGM & Posting of Annual Report &Accounts
21st Nov 20241:32 pmRNSExercise of Share Options and Total Voting Rights
20th Nov 20248:47 amRNSExercise of Share Options and Total Voting Rights
28th Oct 20241:37 pmRNSExercise of Share Options and Total Voting Rights
21st Oct 20247:00 amRNSFinal Results
1st Oct 20247:00 amRNSNotice of Preliminary Results
20th Sep 20247:00 amRNSDirector/PDMR Shareholding
19th Sep 20241:13 pmRNSExercise of Share Options and Total Voting Rights
12th Sep 20247:00 amRNSFDA 510(k) submission for Tristel OPH
2nd Sep 20247:00 amRNSConfirmation of CEO Transition, Directorate Change
6th Aug 20243:32 pmRNSExercise of Share Options and Total Voting Rights
22nd Jul 20247:00 amRNSTrading Update
4th Jul 20243:43 pmRNSExercise of Share Options and Total Voting Rights
11th Jun 20245:48 pmRNSDirector/PDMR Shareholding
11th Jun 20243:50 pmRNSHolding(s) in Company
10th Jun 20247:00 amRNSAppointment of CEO
8th May 20247:00 amRNSTristel™ ULT case study
7th May 20247:00 amRNSExercise of Share Options and Total Voting Rights
16th Apr 20242:04 pmRNSDirector/PDMR Shareholding
15th Apr 20245:56 pmRNSExercise of Share Options and Total Voting Rights
19th Mar 20249:25 amRNSExercise of Share Options and Total Voting Rights
27th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
26th Feb 20247:01 amRNSHalf-year Report
26th Feb 20247:00 amRNSUK and EU regulatory approval update
8th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
1st Feb 20247:00 amRNSNotice of Interim Results
25th Jan 20247:00 amRNSExercise of Share Options and Total Voting Rights
23rd Jan 20247:00 amRNSCanadian regulatory approval for Tristel ULT
10th Jan 20242:27 pmRNSDirector/PDMR Shareholding
19th Dec 202312:02 pmRNSResult of AGM
19th Dec 20237:00 amRNSAGM Statement
7th Dec 20232:05 pmRNSExercise of Share Options and Total Voting Rights
1st Dec 20237:00 amRNSExercise of Share Options and Total Voting Rights
29th Nov 202312:40 pmRNSExercise of Share Options and Total Voting Rights
7th Nov 202311:00 amRNSExercise of Share Options and Total Voting Rights
16th Oct 20237:00 amRNSAudited Preliminary Results
12th Oct 20237:00 amRNSAdditional Investor Presentation
10th Oct 20234:45 pmRNSExercise of Share Options and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.